• Publications
  • Influence
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir.Expand
  • 766
  • 31
  • PDF
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
SummaryThis article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the lastExpand
  • 749
  • 28
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for enhancing the levels of other peptidomimetic HIV protease inhibitors inExpand
  • 396
  • 20
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Ritonavir is 1 of the 4 potent synthetic HIV protease inhibitors, approved by the US Food and Drug Administration (FDA) between 1995 and 1997, that have revolutionised HIV therapy. The extent of oralExpand
  • 401
  • 20
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
ABT-378 is a potent in vitro inhibitor of the HIV protease and is currently being developed for coadministration with another HIV protease inhibitor, ritonavir, as an oral therapeutic treatment forExpand
  • 161
  • 12
  • PDF
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
ABSTRACT The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using theExpand
  • 404
  • 10
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant
BACKGROUND Because traditional therapies for rheumatoid arthritis (RA) such as methotrexate (MTX) do not produce an adequate response in many patients, newer therapies that block the proinflammatoryExpand
  • 263
  • 9
  • PDF
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.
The multiple-dose pharmacokinetics of ritonavir were investigated in four groups of human immunodeficiency virus-positive male subjects (with 16 subjects per group) under nonfasting conditions; a 3:1Expand
  • 176
  • 8
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *
To assess the pharmacokinetic interaction between ritonavir and saquinavir.
  • 164
  • 8
Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
ABSTRACT The pharmacokinetic interaction between indinavir and ritonavir was evaluated in five groups of healthy adult volunteers to explore the potential for twice-daily (b.i.d.) dosing of thisExpand
  • 143
  • 8